Reasons for discontinuation of treatment
| . | ET (n = 65) . | PV (n = 50) . | Total (N = 115) . |
|---|---|---|---|
| Study closure | 22 (33.8) | 13 (26.0) | 35 (30.4) |
| Treatment of 48 mo completed | 18 (27.7) | 12 (24.0) | 30 (26.1) |
| AE | 7 (10.8) | 9 (18.0) | 16 (13.9) |
| Disease progression | 7 (10.8) | 6 (12.0) | 13 (11.3) |
| Refused further treatment | 7 (10.8) | 5 (10.0) | 12 (10.4) |
| Developed other primary solid tumors* | 2 (3.1) | 2 (4.0) | 4 (3.5) |
| Removed to receive nonprotocol therapy? | 2 (3.1) | 0 (0.0) | 2 (1.7) |
| Noncompliance | 0 (0.0) | 1 (2.0) | 1 (0.9) |
| Other† | 0 (0.0) | 2 (4.0) | 2 (1.7) |
| . | ET (n = 65) . | PV (n = 50) . | Total (N = 115) . |
|---|---|---|---|
| Study closure | 22 (33.8) | 13 (26.0) | 35 (30.4) |
| Treatment of 48 mo completed | 18 (27.7) | 12 (24.0) | 30 (26.1) |
| AE | 7 (10.8) | 9 (18.0) | 16 (13.9) |
| Disease progression | 7 (10.8) | 6 (12.0) | 13 (11.3) |
| Refused further treatment | 7 (10.8) | 5 (10.0) | 12 (10.4) |
| Developed other primary solid tumors* | 2 (3.1) | 2 (4.0) | 4 (3.5) |
| Removed to receive nonprotocol therapy? | 2 (3.1) | 0 (0.0) | 2 (1.7) |
| Noncompliance | 0 (0.0) | 1 (2.0) | 1 (0.9) |
| Other† | 0 (0.0) | 2 (4.0) | 2 (1.7) |